Observational studyKidney3602026
Impact of Left Ventricular Geometry on All-Cause Mortality in Patients Undergoing Hemodialysis: A Longitudinal Observational Study.
Observational study in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
key pointsWe evaluated the association between the four categories of left ventricular geometry and all-cause mortality in patients undergoing hemodialysis. Concentric hypertrophy was the most prevalent, followed by concentric remodeling, and these were associated with a high risk of mortality. Echocardiography screening for evaluating the four categories of left ventricular geometry may be useful for risk prediction in patients undergoing hemodialysis.
backgroundLeft ventricular (LV) geometry, which is classified into four categories on the basis of left ventricular mass index and relative wall thickness, can predict mortality more accurately than the presence of LV hypertrophy alone in patients with hypertension. However, this association remains inconclusive in patients undergoing maintenance hemodialysis.
methodsWe conducted a retrospective multicenter cohort study involving patients undergoing maintenance hemodialysis in Japan who underwent echocardiography between October 2006 and December 2021. The exposure of interest was LV geometry abnormalities (concentric remodeling, eccentric hypertrophy, and concentric hypertrophy). The primary outcome of this study was all-cause death.
resultsAmong the 2228 patients included in the analysis (mean age, 67 years; 67% male individuals; median dialysis vintage, 1.5 years), 476 (21%) had normal geometry, 592 (27%) had concentric remodeling, 493 (22%) had eccentric hypertrophy, and 667 (30%) had concentric hypertrophy. During a median follow-up period of 3.8 years, 825 patients (37%) died. Compared with patients with normal geometry, those with concentric hypertrophy (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.06 to 1.63) and concentric remodeling (aHR, 1.27; 95% CI, 1.02 to 1.58) had a higher risk of mortality. Eccentric hypertrophy was associated with a similar risk of mortality (aHR, 1.03; 95% CI, 0.81 to 1.30) compared with normal geometry.
conclusionsApproximately 80% of patients undergoing maintenance hemodialysis exhibited abnormal LV geometry, with concentric hypertrophy being the most common pattern, followed by concentric remodeling. These abnormalities were associated with a higher risk of all-cause mortality compared with normal geometry. Risk prediction on the basis of the presence or absence of LV hypertrophy cannot consider concentric remodeling; therefore, echocardiography screening for evaluating the four categories of LV geometry may be beneficial in patients undergoing hemodialysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.